
Booster doses for the ongoing COVID-19 pandemic are under consideration in many countries. The study report a three-month follow-up of 700 participants in a fourth vaccine dose study, comparing BNT162b2 and mRNA1273, administered four months after a third BNT162b2 dose. The primary outcomes are the levels of IgG, neutralizing antibodies, and microneutralization. The secondary effects are IgA and T cell activation levels and clinical outcomes of SARS-CoV-2 infection and substantial symptomatic disease. The results are informative for further boosting policy-making.
Like
Save
Share